Finasteride is an inexpensive prescription oral medication used for an enlarged prostate and pattern hair loss. Its clearest benefits are fewer complications from an enlarged prostate and slower hair loss, plus fewer prostate cancer diagnoses, mostly of slow-growing tumors. Whether it lengthens life is unproven. Sexual side effects affect a minority of users; mood effects and symptoms persisting after stopping are contested. Benefits fade once the drug is stopped. (Full Review)
| Marker | Target | Why |
|---|---|---|
| PSA | 0–4.0 ng/mL; on finasteride, track change from the lowest on-treatment value | Safety check: a confirmed rise prompts evaluation |
| Serum DHT | Roughly 30–85 ng/dL in men, varying by assay; track percentage suppression from own baseline | Confirms drug effect |
| Total testosterone | Roughly 264–916 ng/dL in men | Expected to rise about 15% |
| HbA1c | 4.0–5.6% | Safety check: diabetes signal |
| IIEF-5 score | No established target; track change from own baseline | Safety check: a sustained fall prompts dose review |
| PHQ-9 score | No established target; track change from own baseline | Safety check: new depression or suicidal thoughts stop 1 mg use |
| IPSS (prostate users) | No established target; track change from own baseline | Expected to change: improvement |
| Semen analysis (if planning conception) | Sperm concentration ≥16 million/mL | Safety check: reduced quality prompts pausing |
Cadence: Baseline before the first dose; then 3 months, 6 months, then every 12 months: questionnaires at each visit, PSA re-baselined at 6 months and then checked annually, HbA1c annually; hair photographs at 6 and 12 months